



Phenotypes and Endotypes in Interstitial Lung Diseases

Guest Editor:

Dr. Francesco Amati

Department of Biomedical
Sciences, Humanitas University,
Via Rita Levi Montalcini 4, 20072
Milan, Italy

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 entities of either known or unknown etiology. ILD heterogeneity manifests at many levels, including symptoms, disease course, radiological and histological features, and biological underpinnings. This heterogeneity has been a substantial barrier to understanding disease mechanisms and developing effective and personalized treatments. Recent data suggest that different ILDs can share similar pathogenetic and biological pathways and thus be amenable to the same treatment. A growing amount of evidence points towards subgroups characterization of ILDs through endotypes, defined by specific genetic and molecular biomarkers. Thus, the future of ILDs lies in precision medicine approaches based on phenotypic and endotypic features. The aim of the Special Issue “Phenotypes and Endotypes in Interstitial Lung Diseases” is to outline the status of knowledge in this field.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)